News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
865,468 Results
Type
Article (87933)
Company Profile (730)
Press Release (776773)
Multimedia
Podcasts (227)
Webinars (34)
Section
Business (232969)
Career Advice (4154)
Deals (39937)
Drug Delivery (158)
Drug Development (91347)
Employer Resources (207)
FDA (18368)
Job Trends (17464)
News (397362)
Policy (39873)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (3028)
Academic (1)
Accelerated approval (45)
Adcomms (33)
Allergies (146)
Alliances (56799)
ALS (191)
Alzheimer's disease (1868)
Antibody-drug conjugate (ADC) (451)
Approvals (18527)
Artificial intelligence (607)
Autoimmune disease (279)
Automation (47)
Bankruptcy (403)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (237)
Biotechnology (452)
Bladder cancer (171)
Brain cancer (62)
Breast cancer (633)
Cancer (5144)
Cardiovascular disease (350)
Career advice (3586)
Career pathing (48)
CAR-T (333)
CDC (49)
Celiac Disease (2)
Cell therapy (896)
Cervical cancer (39)
Clinical research (77219)
Collaboration (1950)
Company closure (7)
Compensation (1201)
Complete response letters (91)
COVID-19 (2954)
CRISPR (102)
C-suite (973)
Cystic fibrosis (150)
Data (6729)
Decentralized trials (3)
Denatured (86)
Depression (140)
Dermatology (59)
Diabetes (401)
Diagnostics (7145)
Digital health (33)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (327)
Drug pricing (171)
Drug shortages (21)
Duchenne muscular dystrophy (247)
Earnings (99270)
Editorial (67)
Employer branding (25)
Employer resources (174)
Events (134560)
Executive appointments (919)
FDA (21188)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (13)
Frontotemporal dementia (35)
Funding (1482)
Gene editing (221)
Generative AI (62)
Gene therapy (720)
GLP-1 (1002)
Government (5398)
Grass and pollen (4)
Guidances (291)
Healthcare (20851)
HIV (66)
Huntington's disease (57)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (94)
Immunology and inflammation (310)
Immuno-oncology (96)
Indications (142)
Infectious disease (3260)
Inflammatory bowel disease (234)
Inflation Reduction Act (14)
Influenza (114)
Intellectual property (236)
Interviews (820)
IPO (17830)
IRA (46)
Job creations (5203)
Job search strategy (2870)
JPM (69)
Kidney cancer (19)
Labor market (109)
Layoffs (657)
Leadership (46)
Legal (10100)
Liver cancer (92)
Longevity (31)
Lung cancer (687)
Lymphoma (379)
Machine learning (59)
Management (66)
Manufacturing (927)
MASH (184)
Medical device (14482)
Medtech (14536)
Mergers & acquisitions (22911)
Metabolic disorders (1253)
mRNA (231)
Multiple sclerosis (178)
NASH (23)
Neurodegenerative disease (425)
Neuropsychiatric disorders (99)
Neuroscience (3277)
Neurotech (1)
NextGen: Class of 2026 (7690)
Non-profit (5097)
Now hiring (77)
Obesity (615)
Opinion (351)
Ovarian cancer (199)
Pain (190)
Pancreatic cancer (216)
Parkinson's disease (337)
Partnered (33)
Patents (478)
Patient recruitment (576)
Peanut (61)
People (66883)
Pharmaceutical (126)
Pharmacy benefit managers (20)
Phase 1 (23950)
Phase 2 (33648)
Phase 3 (25163)
Pipeline (6854)
Policy (317)
Postmarket research (3550)
Preclinical (10770)
Press Release (72)
Prostate cancer (251)
Psychedelics (62)
Radiopharmaceuticals (315)
Rare diseases (1007)
Real estate (7435)
Recruiting (81)
Regulatory (28994)
Reports (72)
Research institute (2718)
Resumes & cover letters (653)
Rett syndrome (28)
RNA editing (25)
RSV (82)
Schizophrenia (168)
Series A (266)
Series B (184)
Service/supplier (25)
Sickle cell disease (99)
Special edition (31)
Spinal muscular atrophy (183)
Sponsored (53)
Startups (4352)
State (2)
Stomach cancer (16)
Supply chain (92)
Tariffs (79)
The Weekly (138)
Vaccines (1101)
Venture capital (115)
Weight loss (392)
Women's health (96)
Worklife (24)
Date
Today (183)
Last 7 days (726)
Last 30 days (2655)
Last 365 days (25679)
2026 (9544)
2025 (25580)
2024 (34043)
2023 (42564)
2022 (53928)
2021 (58721)
2020 (57664)
2019 (51336)
2018 (39119)
2017 (37189)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1281)
Alabama (92)
Alaska (6)
Arizona (302)
Arkansas (9)
Asia (51529)
Australia (9084)
California (11255)
Canada (2813)
China (1283)
Colorado (364)
Connecticut (471)
Delaware (350)
Europe (118032)
Florida (1481)
Georgia (301)
Hawaii (4)
Idaho (65)
Illinois (749)
India (73)
Indiana (517)
Iowa (22)
Japan (420)
Kansas (138)
Kentucky (29)
Louisiana (16)
Maine (61)
Maryland (1429)
Massachusetts (8445)
Michigan (267)
Minnesota (512)
Mississippi (5)
Missouri (87)
Montana (30)
Nebraska (30)
Nevada (124)
New Hampshire (60)
New Jersey (2941)
New Mexico (29)
New York (2957)
North Carolina (1582)
North Dakota (9)
Northern California (5644)
Ohio (300)
Oklahoma (21)
Oregon (51)
Pennsylvania (2191)
Puerto Rico (28)
Rhode Island (36)
South America (1660)
South Carolina (16)
South Dakota (1)
Southern California (4396)
Tennessee (71)
Texas (1633)
United States (38984)
Utah (243)
Vermont (1)
Virginia (198)
Washington D.C. (54)
Washington State (927)
West Virginia (2)
Wisconsin (99)
865,468 Results for "gsk bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the first quarter, emerging as the pharma’s top-selling product.
April 29, 2026
·
2 min read
·
Tristan Manalac
Weight loss
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.
May 7, 2026
·
2 min read
·
Tristan Manalac
Regulatory
GSK again pulls application for leucovorin, touted by FDA as potential autism treatment
GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to treat cerebral folate deficiency with “autistic features.”
April 10, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
April 20, 2026
·
3 min read
Press Releases
Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland
April 1, 2026
·
3 min read
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated the partnership.
December 8, 2025
·
2 min read
·
Tristan Manalac
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.
November 21, 2025
·
3 min read
·
Tristan Manalac
1 of 86,547
Next
